Drugs / AZD5423
last change Jan 2015 re-read 2 minutes ago

AZD5423

Other / unclassified targets NR3C1

Developed for
asthma · chronic obstructive pulmonary disease
Investigated by
AstraZeneca

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT01635985 Aug → Dec 2012 AstraZeneca Completed No outcome recorded
Phase 1 NCT01338350 Jun → Dec 2011 AstraZeneca Completed No outcome recorded
Phase 1 NCT01310322 Apr → Oct 2011 asthma AstraZeneca Completed No outcome recorded
Phase 1 NCT01037504 Jan → Apr 2010 AstraZeneca Completed No outcome recorded
Phase 1 NCT00963183 Aug → Nov 2009 AstraZeneca Completed No outcome recorded
Phase 22 trials
Phase 2 NCT01555099 Apr 2012 → Apr 2013 chronic obstructive pulmonary disease AstraZeneca Completed No outcome recorded
Phase 2 NCT01225549 Nov 2010 → Dec 2011 asthma AstraZeneca Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as AZD5423 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01555099
6

NCT01037504

NCT01635985

NCT01338350

NCT00963183

NCT01310322

NCT01225549

Action Activate “nonsteroidal glucocorticoid receptor agonist AZD5423” PMID 25473939 Jan 2015
Modality Other / unclassified “inhaled nonsteroidal glucocorticoid receptor agonist, AZD5423” PMID 25473939 Jan 2015
Route Inhaled “Solution for nebulisation, inhaled.” NCT00963183
Target NR3C1 “Glucocorticoid receptor modulator” CHEMBL4072756